2Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescene in situ hybrdization. Oncogene, 1996, 13: 63-72.
3Ravdin PM. Should HER-2 status be routinely measured for all breast cancer patients? Semin Oncol, 1999, 26: 117-123.
4Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2 overexpressing human breast cancer xenografts. Cancer Res, 1998, 58: 2825-2831.
5Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction tHERapy of solid tumors. Am J Pathol, 1997, 151: 1523-1530.
6Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol,1999, 17 : 2639-2648.
7Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of HerceptinTM(trastuzumab, humanized anti-HER2 antibody) as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer (HER2 +/MBC). Breast Cancer Res Treat, 1998, 50: 232a.
8Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer,2001, 37: 18-24.
9Slamon D, Leyland-Jones B, Shak S, et al. Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 +/MBC ) markedly increases anticancer activity: a randomized multinational controlled phase Ⅲ trial. Proc Am Soc Clin Oncol, 1998, 17:98a.
10Norton L, Slamon D, Leyland-Jones B, et al. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2 + ) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol,1999, 18: 127a.
2Zheng-Xu Wang~1 Gui-Fang Hu~1 Hong-Yang Wang~2 Meng-Chao Wu~2 1 Department of General Surgery,Chinese PEA General Hospital of Lanzhou Military Command,Lanzhou 730050,Gansu Province,China2 Eastern Hepatobilliary Surgical Hospital,Second Military Medical University,Shanghai 200438,China.Expression of liver cancer associated gene HCCA3[J].World Journal of Gastroenterology,2001,7(6):821-825. 被引量：9
6Takako S,Yasuyoshi O,Mizuho K,et al.The distribution of fibronectin and laminin in the murine periodontal membrane,indicating possible functional roles in the apical migration of the junctional epithelium[J].Archs oral Biol,1996,41(8/9):885-891.
7Oksanen J,Sorokin LM,Virtanen I and Hormia M.The junctional epithelium around murine teeth differs from gingival epithelium in its basement mambrane composition[J].J Dent Res,2001,80(12):2 093-2 097.
8Ishida K, Katsuyama T, Sugiyama A, et al. Immunohisto- chemical evaluation of lymphnode micrometastases from gas- tric carcinomas[J]. Cancer , 1997,79 (6) : 1069-1076.
9张大泽,徐光伟.肿瘤学(中册)[M].天津:天津科学技术出版社,1994:1145-1154.
10Bohinski RJ, DiLauro R, Whitsett JA. The lung-specific sur- factant protein B gene promoter is a target for thyroid tran- scription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis[J]. Mol Cell Biol ,1994, 14 (9):5671-5681.
